Laurence Belkoff, DO
Urology · Bala Cynwyd, PANPI 1689679938
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.6%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 18.3%. 2025 is the largest year on record at $15,095, 2.4 times the $6,330 reported in 2019. Among urology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 635 payments — averaging $74.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$9K
- Bayer$7K
- Astellas Pharma US Inc$6K
- Urogen Pharma, Inc.$6K
- Janssen Scientific Affairs, LLC$5K
- Immunitybio, Inc.$2K
- plus $14K from 54 others
Across 1,495 payments — averaging $12,459 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$11.9M
- Janssen Research & Development, LLC$2.6M
- Blue Earth Diagnostics$856K
- AstraZeneca$749K
- Bayer$731K
- E.r. Squibb & Sons, L.L.C.$422K
- plus $1.4M from 18 others
What the payments were for
- Consulting fees$14,66031%
- Speaking & faculty fees$11,23524%
- Travel & lodging$1,0412%
- Food & beverage$19,74342%
- Education$7422%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$7,985
- Nubeqa$5,707
- ZUSDURI$4,875
- AKEEGA$3,843
- ANKTIVA$1,619
- JATENZO$1,500
- PROVENGE$558
- XTANDI$448
- JELMYTO$372
- Xofigo$342
- CVAC Aspiration System$310
- FIBER DUST$264
- LithoVue$250
- Axumin$227
- UroLift$219
- ILLUCCIX$206
- ORGOVYX$174
- INTERSTIM$161
- GENERAL KIDNEY STONE DISEASE$152
- ADSTILADRIN$146
How this compares
$47,421 in reported general payments places this provider in the 95th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 16 | $244,865 |
| OrgovyxRelugolix | 78 | $224,486 |
| MyrbetriqMirabegron | 181 | $123,992 |
| Abiraterone Acetate | 15 | $87,221 |
| GemtesaVibegron | 139 | $79,250 |
| Trospium Chloride ErTrospium Chloride | 83 | $13,926 |
| Tamsulosin Hcl | 740 | $10,093 |
| JatenzoTestosterone Undecanoate | 14 | $7,652 |
| Tolterodine Tartrate ErTolterodine Tartrate | 122 | $7,593 |
| Solifenacin Succinate | 88 | $6,292 |
| Dutasteride | 142 | $5,187 |
| CialisTadalafil | 14 | $4,066 |
| Testosterone | 33 | $2,497 |
| Finasteride | 181 | $2,271 |
| Oxybutynin Chloride ErOxybutynin Chloride | 50 | $1,721 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $634 | $303,736217 claims |
| Johnson & JohnsonErleada | $8,695 | $244,86516 claims |
| Astellas Pharma US IncMyrbetriq | $6,425 | $123,992181 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $4,512 | $87,22115 claims |
| Clarus Therapeutics Inc.Jatenzo | $516 | $7,65214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 596 urology providers in Pennsylvania.
Other urology in Bala Cynwyd
- John AndersonBethlehem$2.1M
- Demetrius BagleyPhiladelphia$739K
- Paul SieberLancaster$631K
- Daniel EunPhiladelphia$226K
- Leonard GomellaPhiladelphia$190K
- Anthony DimatteoButler$189K
- Angelo BaccalaAllentown$166K
- Phillip GinsbergPhiladelphia$145K
- Edouard TrabulsiPhiladelphia$137K
- Siobhan HartiganPhiladelphia$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.